1344 N17350 combines selective cancer killing with adaptive immune activation to eradicate tumors
1344 N17350 combines selective cancer killing with adaptive immune activation to eradicate tumors
About this item
Full title
Author / Creator
Publisher
London: BMJ Publishing Group Ltd
Journal title
Language
English
Formats
Publication information
Publisher
London: BMJ Publishing Group Ltd
Subjects
More information
Scope and Contents
Contents
BackgroundStudies have shown that ELANE- a neutrophil-derived serine protease – kills a wide range of cancer cells without harming non-cancer cells by cleaving CD95 to liberate the death domain. This liberated death domain interacts with histone H1, whose differential expression between cancer and non-cancer cell contributes to selective cancer kil...
Alternative Titles
Full title
1344 N17350 combines selective cancer killing with adaptive immune activation to eradicate tumors
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_095ee82a6ed6457695deff934997acac
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_095ee82a6ed6457695deff934997acac
Other Identifiers
E-ISSN
2051-1426
DOI
10.1136/jitc-2023-SITC2023.1344
